{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:34:34Z","timestamp":1783640074561,"version":"3.55.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oral. Health"],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) are a revolutionary class of antineoplastic therapy that restore anti-tumor immunity. Consequences of this enhanced immune response include a multitude of immune related adverse events (irAEs) that can affect any body system, including the mouth. Orofacial irAEs reproduce features of numerous immune-mediated conditions, including oral lichen planus, mucous membrane pemphigoid, and Sj\u00f6gren syndrome, among others. The aim of this review is to summarize known orofacial irAEs and to familiarize oral healthcare providers with how to identify and manage these toxicities as part of the care team for patients treated with ICIs.<\/jats:p>","DOI":"10.3389\/froh.2022.968157","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T09:29:53Z","timestamp":1660210193000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Immune checkpoint inhibitors in cancer therapy: Review of orofacial adverse events and role of the oral healthcare provider"],"prefix":"10.3389","volume":"3","author":[{"given":"Brittany A.","family":"Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ali","family":"Shazib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio","family":"de Abreu Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piamkamon","family":"Vacharotayangul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Sonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fedele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel S.","family":"Treister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11684-019-0735-3","article-title":"Advances on immune-related adverse events associated with immune checkpoint inhibitors","volume":"15","author":"Fan","year":"2021","journal-title":"Front Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s40265-021-01539-5","article-title":"Dostarlimab: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs."},{"key":"B6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice guideline summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J Oncol Pract."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.3390\/curroncol28060373","article-title":"The price of success: immune-related adverse events from immunotherapy in lung cancer","volume":"28","author":"Coschi","year":"2021","journal-title":"Curr Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic immune-related adverse events following adjuvant anti-Pd-1 therapy for high-risk resected melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol."},{"key":"B11","volume-title":"Cancer Therapy Evaluation Program","year":"2017"},{"key":"B12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, Version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw."},{"key":"B13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1053\/j.seminoncol.2019.10.003","article-title":"A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients","volume":"46","author":"Cortellini","year":"2019","journal-title":"Semin Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/cncr.33436","article-title":"Oral side effects of immune checkpoint inhibitor therapy (ICIT): an analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019","volume":"127","author":"Xu","year":"2021","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.6004\/jnccn.2020.7697","article-title":"Clinical characteristics and outcomes of oral mucositis associated with immune checkpoint inhibitors in patients with cancer","volume":"19","author":"Jacob","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/odi.13964","article-title":"Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"28","author":"Klein","year":"2021","journal-title":"Oral Dis"},{"key":"B17","volume-title":"The Concise Oral Exam","year":"2018"},{"key":"B18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/odi.13218","article-title":"Oral immune-related adverse events associated with PD-1 inhibitor therapy: a case series","volume":"26","author":"Shazib","year":"2020","journal-title":"Oral Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e464","DOI":"10.1111\/jdv.14284","article-title":"Oral lichenoid reactions associated with anti-PD-1\/PD-L1 therapies: clinicopathological findings","volume":"31","author":"Sibaud","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/j.oooo.2020.06.014","article-title":"Severe oral erosive lichenoid reaction to pembrolizumab therapy","volume":"130","author":"Bhattacharyya","year":"2020","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1111\/jdv.16036","article-title":"Mucous membrane pemphigoid and lichenoid reactions after immune checkpoint inhibitors: common pathomechanisms","volume":"34","author":"F\u00e4ssler","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/odi.12639","article-title":"Oral mucous membrane pemphigoid and pemphigus vulgaris-a retrospective two-center cohort study","volume":"23","author":"Sultan","year":"2017","journal-title":"Oral Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5070\/D3239036484","article-title":"Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab","volume":"23","author":"Sundaresan","year":"2017","journal-title":"Dermatol Online J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/1346-8138.13810","article-title":"Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy","volume":"44","author":"Nomura","year":"2017","journal-title":"J Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000485910","article-title":"A case of erythema multiforme major developed after sequential use of two immune checkpoint inhibitors, nivolumab and ipilimumab, for advanced melanoma: possible implication of synergistic and\/or complementary immunomodulatory effects","volume":"10","author":"Utsunomiya","year":"2018","journal-title":"Case Rep Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1111\/ijd.14811","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int J Dermatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"102596","DOI":"10.1016\/j.autrev.2020.102596","article-title":"Risk of scleroderma according to the type of immune checkpoint inhibitors","volume":"19","author":"Terrier","year":"2020","journal-title":"Autoimmun Rev."},{"key":"B30","first-page":"864","article-title":"De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: a retrospective analysis","volume-title":"J Am Acad Dermatol.","author":"Bui","year":"2021"},{"key":"B31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/CJI.0000000000000288","article-title":"Linear IgA disease of the gingiva following nivolumab therapy","volume":"42","author":"Jonna","year":"2019","journal-title":"J Immunother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/1346-8138.14205","article-title":"Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: a report of two cases and published work review","volume":"45","author":"Obara","year":"2018","journal-title":"J Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fmed.2018.00268","article-title":"Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed death-1\/ programmed death-ligand 1: a case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the literature","volume":"5","author":"Zumelzu","year":"2018","journal-title":"Front Med."},{"key":"B36","first-page":"807","article-title":"Severe oral mucositis: a rare adverse event of pembrolizumab","volume":"17","author":"Lederhandler","year":"2018","journal-title":"J Drugs Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2324709620914796","DOI":"10.1177\/2324709620914796","article-title":"Stevens-Johnson syndrome-like reaction after exposure to pembrolizumab and recombinant zoster vaccine in a patient with metastatic lung cancer","volume":"8","author":"Riano","year":"2020","journal-title":"J Investig Med High Impact Case Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1136\/ard.2009.110619","article-title":"Sicca\/Sj\u00f6gren's syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)","volume":"37","author":"Ramos-Casals","year":"2019","journal-title":"Clin Exp Rheumatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/odi.14000","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","author":"Harris","year":"2021","journal-title":"Oral Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12903-016-0296-7","article-title":"A randomized, double-blind, placebo-controlled clinical trial of fluoride varnish in preventing dental caries of Sj\u00f6gren's syndrome patients","volume":"16","author":"Xin","year":"2016","journal-title":"BMC Oral Health."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2217\/imt-2020-0108","article-title":"Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report","volume":"12","author":"Pundole","year":"2020","journal-title":"Immunotherapy."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1016\/j.oraloncology.2015.08.014","article-title":"Osteonecrosis of the jaw a new complication related to Ipilimumab","volume":"51","author":"Owosho","year":"2015","journal-title":"Oral Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ccr3.3418","article-title":"New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy","volume":"9","author":"Guida","year":"2021","journal-title":"Clin Case Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jormas.2020.05.001","article-title":"Medication-related osteonecrosis of the jaw related to epacadostat and pembrolizumab","volume":"121","author":"Decaux","year":"2020","journal-title":"J Stomatol Oral Maxillofac Surg."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e227722","DOI":"10.1001\/jamanetworkopen.2022.7722","article-title":"Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis","volume":"5","author":"Farooq","year":"2022","journal-title":"JAMA Netw Open."}],"container-title":["Frontiers in Oral Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/froh.2022.968157\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T15:38:16Z","timestamp":1660664296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/froh.2022.968157\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":46,"alternative-id":["10.3389\/froh.2022.968157"],"URL":"https:\/\/doi.org\/10.3389\/froh.2022.968157","relation":{},"ISSN":["2673-4842"],"issn-type":[{"value":"2673-4842","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]},"article-number":"968157"}}